Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - atomoxetinum - capsule - atomoxetinum 18 mg ut atomoxetini hydrochloridum, dimeticonum 350, amylum pregelificatum, matériel de la capsule: natrii laurilsulfas corresp. natrium 5.6 µg, gelatina, e 171, e 172 (flavum), encre: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), pro capsula. - simpaticomimetici di azione centrale, camere non-stimolante - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - atomoxetinum - capsule - atomoxetinum 25 mg ut atomoxetini hydrochloridum, dimeticonum 350, amylum pregelificatum, matériel de la capsule: natrii laurilsulfas corresp. natrium 5.6 µg, gelatina, e 132, e 171, encre: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), pro capsula. - simpaticomimetici di azione centrale, camere non-stimolante - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - atomoxetinum - capsule - atomoxetinum 40 mg ut atomoxetini hydrochloridum, dimeticonum 350, amylum pregelificatum, matériel de la capsule: natrii laurilsulfas corresp. natrium 5.6 µg, gelatina, e 132, e 171, encre: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), pro capsula. - simpaticomimetici di azione centrale, camere non-stimolante - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - atomoxetinum - capsule - atomoxetinum 60 mg ut atomoxetini hydrochloridum, dimeticonum 350, amylum pregelificatum, matériel de la capsule: natrii laurilsulfas corresp. natrium 7.2 µg, gelatina, e 132, e 171, e 172 (flavum), encre: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), pro capsula. - simpaticomimetici di azione centrale, camere non-stimolante - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - atomoxetinum - capsule - atomoxetinum 80 mg ut atomoxetini hydrochloridum, dimeticonum, amylum pregelificatum, matériel de la capsule: natrii laurilsulfas corresp. natrium 6.9 µg, gelatina, e 171, e 172 (flavum), e 172 (rubrum), encre: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), pro capsula. - simpaticomimetici di azione centrale, camere non-stimolante - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - atomoxetinum - capsule - atomoxetinum 100 mg ut atomoxetini hydrochloridum, dimeticonum, amylum pregelificatum, matériel de la capsule: natrii laurilsulfas corresp. natrium 8.4 µg, gelatina, e 171, e 172 (rubrum), e 172 (flavum), encre: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), pro capsula. - simpaticomimetici di azione centrale, camere non-stimolante - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - atomoxetinum - soluzione buvable - atomoxetinum 4 mg ut atomoxetini hydrochloridum, natrii dihydrogenophosphas dihydricus, acidum phosphoricum dilutum, sorbitolum liquidum cristallisabile corresp. sorbitolum 33 mg, xylitolum, aromatica (framboise), propylenglycolum 9.8 mg, sucralosum, natrii hydroxidum, e 211 0.8 mg, aqua purificata q.s. ad solutionem pro 1 ml corresp. natrium 2.64 mg. - tdah - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - ixekizumabum - soluzione per iniezione in pre-riempita penna - ixekizumabum 80 mg, saccharum, polysorbatum 80, natrii hydroxidum q.s. ad ph, aqua ad iniectabile, ad solutionem pro 1 ml. - psoriasis en plaques chez l'adulte, arthrite psoriasique, psoriasis en plaques chez l'enfant et l'adolescent à partir de 6 ans et d'un poids corporel d'au moins 25 kg, spondylarthrite ankylosante, spondyloarthrite axiale non radiographique - biotechnologika

Europeiska unionen - italienska - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - neoplasie prostatiche - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - insulinum glarginum - soluzione iniettabile - insulinum glarginum 3.64 mg corresp. insulinum glarginum 100 u., glycerolum, metacresolum, zincum ut zinci oxidum, acidum hydrochloridum dilutum, natrii hydroxidum corresp. natrium 0.04 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - il diabete mellito - biotechnologika